Malignant Anaplastic Astrocytoma

Malignant Anaplastic astrocytoma, IDH-mutant, grade 3 is a cancer that starts in star-shaped support cells of the brain called astrocytes. “IDH-mutant” means the tumor’s cells carry a change in a gene called IDH1 or IDH2. “Grade 3” tells us it grows faster and behaves more aggressively than grade 2, but it is still different from grade 4 disease (grade 4 is worse and used to be called glioblastoma). Doctors now diagnose and grade this tumor by looking at the tissue under a microscope and by checking molecular markers such as IDH, ATRX, TP53, and 1p/19q status. If the tumor has an IDH mutation, does not have a 1p/19q codeletion, and shows high-grade features (like many dividing cells), it is called astrocytoma, IDH-mutant, grade 3. PMC+1

Anaplastic astrocytoma is a fast-growing brain tumor that starts from star-shaped support cells called astrocytes. “Anaplastic” means the cells look very abnormal and divide quickly. In the modern WHO system, most tumors once called “anaplastic astrocytoma” are now labeled astrocytoma, IDH-mutant, grade 3. Doctors confirm the diagnosis by the way the cells look under the microscope and by testing for key gene changes, especially IDH1/IDH2 mutation, ATRX loss, and TP53 mutation; tumors without IDH mutation are usually not called astrocytoma grade 3 anymore. This change matters because treatment and prognosis follow the molecular type. PMC+2PMC+2

This tumor is diffuse, which means cancer cells infiltrate into nearby brain tissue. It often appears in young and middle-aged adults (around the 30s–40s), and the most common first symptom is a seizure or gradually worsening neurological problems (like weakness, language or vision changes) depending on where in the brain it grows. MRI is the main imaging test; a small surgery or needle biopsy is done to get tissue for the combined microscopic and molecular diagnosis. NCBI+1

Other names

You may see several names for the same condition in older articles or different clinics:

• Anaplastic astrocytoma (AA), WHO grade III – the older term now replaced by “astrocytoma, IDH-mutant, grade 3.” Radiopaedia

• Diffuse astrocytoma, grade 3 – another legacy phrase meaning the same entity. PMC

• Malignant astrocytoma (grade 3) – a non-technical, older way to say it is a high-grade astrocytoma but not grade 4. PMC

Types

Doctors don’t subdivide grade-3 IDH-mutant astrocytoma into many formal “types,” but these practical categories help people understand it:

1. By origin

   • Secondary (progressed) tumors: started as a lower-grade IDH-mutant astrocytoma (grade 2) and later became grade 3. MDPI

   • De novo: first shows up already as grade 3. (Less common.) NCBI

2. By IDH gene change

   • IDH1-mutant (most often R132H) – the usual form. Chinese Clinical Oncology

   • IDH2-mutant – less common. PMC

3. By location

   • Hemispheric (frontal/temporal/parietal/occipital) – the typical adult sites; symptoms match the involved lobe. NCBI

Causes and risk factors

For brain tumors, only a few true causes are proven. Most items below are either risk factors (things that increase chance) or biological changes that drive the tumor’s growth once it has started.

1. Ionizing radiation (to the head), especially at younger ages, is the best-established environmental risk for gliomas. PMC+1

2. Li-Fraumeni syndrome (inherited TP53 variant) raises glioma risk. PMC

3. Neurofibromatosis type 1 can increase glioma risk. Roswell Park Comprehensive Cancer Center

4. Lynch syndrome / mismatch-repair gene variants can be associated with high-grade gliomas in some families. PMC

5. Tuberous sclerosis complex increases risk for certain astrocytomas. Roswell Park Comprehensive Cancer Center

6. Family history of glioma (rare familial clustering) modestly increases risk. PMC

7. IDH1 or IDH2 mutation (a hallmark molecular driver that defines this tumor and produces the oncometabolite 2-hydroxyglutarate, reshaping gene regulation). PMC+1

8. TP53 mutation (common driver change in IDH-mutant astrocytoma). Chinese Clinical Oncology

9. ATRX inactivation (leads to alternative telomere lengthening; frequent in IDH-mutant astrocytoma). PMC

10. MGMT promoter methylation (not a “cause” of tumor formation, but an epigenetic change that affects response to alkylating chemotherapy). PMC

11. Progression from a lower-grade IDH-mutant astrocytoma (biological evolution over time). MDPI

12. Temozolomide-induced hypermutation at recurrence (an acquired change after treatment in some tumors; linked to more aggressive recurrences). PMC+1

13. Primary mismatch-repair deficiency (rare; can drive aggressive biology in some IDH-mutant astrocytomas). SpringerLink

14. Age (adults—often 30s–40s—are most affected; risk pattern differs from children). NCBI

15. Male sex has a slight predominance in many gliomas (pattern varies by series). NCBI

16. Genomic copy-number changes (e.g., CDKN2A/B loss is a poor-risk event that actually upgrades an IDH-mutant astrocytoma to grade 4 if homozygously deleted). ScienceDirect

17. Epigenetic reprogramming from IDH mutation (IDH oncometabolite alters methylation landscape, promoting gliomagenesis). MDPI

18. Cell-cycle pathway activation (e.g., PI3K/mTOR, PDGF signaling) during malignant progression. MDPI

19. Prior therapeutic radiation (distinct from diagnostic scans; part of ionizing radiation risk). PMC

20. Most common environmental exposures (like mobile phones) are not proven causes for astrocytoma; evidence to date is inconsistent or negative. (Important for patient reassurance.) PMC

Symptoms

The symptom list depends on where the tumor grows. Because it infiltrates brain tissue, symptoms are often gradual at first.

1. Seizures (very common first sign in IDH-mutant diffuse gliomas). Nature

2. Headaches that get worse over weeks to months (pressure or morning headaches). NCBI

3. Weakness in an arm or leg (motor cortex involvement). NCBI

4. Speech or language problems (dominant frontal/temporal involvement). NCBI

5. Behavior or personality change (frontal lobe). NCBI

6. Memory or thinking problems (frontal/temporal networks). NCBI

7. Vision loss or field cuts (occipital lobe or optic pathways). NCBI

8. Numbness/tingling or sensory loss on one side. NCBI

9. Balance trouble or clumsiness (cerebellar or proprioceptive pathways). NCBI

10. Difficulty reading or understanding (parietal/temporal). NCBI

11. Visual “aura” or brief confusion spells tied to focal seizures. NCBI

12. Fatigue and low energy (multi-factorial—tumor, seizures, medicines). NCBI

13. Nausea/vomiting (raised intracranial pressure). NCBI

14. New onset depression/anxiety related to brain changes and stress. NCBI

15. Progressive symptoms over months rather than days (fits the biology of many IDH-mutant tumors). NCBI

Diagnostic tests

A) Physical exam

1. Full neurological examination – Your clinician checks alertness, orientation, memory, attention, and higher brain functions; looks for asymmetry or focal deficits. This does not diagnose cancer by itself but tells where the brain may be affected and guides which tests to order. NCBI

2. Cranial nerve testing – Simple bedside checks of pupils, eye movements, facial strength, speech and swallowing, and hearing. Abnormal results point toward where the tumor might be pressing or infiltrating. NCBI

3. Motor and reflex assessment – Strength testing, tone, and deep tendon reflexes detect corticospinal tract involvement; asymmetry supports a focal brain process. NCBI

B) Manual bedside tests

4. Confrontation visual fields – You cover one eye at a time while the examiner maps your side vision. Field cuts suggest involvement of optic pathways or occipital lobe. NCBI

5. Romberg test (balance) – Standing with feet together, then eyes closed; sway or fall suggests proprioceptive or cerebellar pathway problems sometimes seen when tumors disrupt sensory networks. NCBI

6. Finger-to-nose and heel-to-shin – Coordination tests that reveal cerebellar or cortical dysfunction (overshoot, tremor, or inaccurate movements). NCBI

C) Lab & pathological tests

7. Stereotactic biopsy or surgical resection with histology – A small piece of tumor is examined under the microscope for increased cellularity, mitoses, and atypia consistent with grade 3. Tissue is essential because modern diagnosis integrates histology with molecular tests. PMC

8. IDH1 R132H immunohistochemistry (IHC) and/or sequencing of IDH1/IDH2 – Detects the defining IDH mutation; if the common R132H stain is negative, labs sequence the genes (especially in younger adults). This separates IDH-mutant astrocytoma from other gliomas. College of American Pathologists+1

9. ATRX immunostaining (loss of nuclear staining) and TP53 (p53) IHC – Support astrocytoma biology (ATRX loss and strong p53 expression are common). Chinese Clinical Oncology

10. 1p/19q codeletion testing (FISH/NGS) – Rules out oligodendroglioma; an IDH-mutant tumor with whole-arm 1p/19q codeletion is an oligodendroglioma, not an astrocytoma. PMC

11. MGMT promoter methylation testing – Helpful prognostic/predictive marker for response to alkylating chemotherapy (like temozolomide), although most evidence is strongest in glioblastoma. Methods include methylation-specific PCR or pyrosequencing. BioMed Central+1

12. Targeted NGS panels – Broader sequencing can identify additional changes (e.g., CDKN2A/B loss, which—if homozygously deleted—upgrades an IDH-mutant astrocytoma to grade 4 under WHO 2021). PMC+1

D) Electrodiagnostic tests

13. Electroencephalography (EEG) – Records brain waves to confirm and localize seizures; useful because seizures are a frequent first symptom in IDH-mutant diffuse gliomas. Nature

14. Somatosensory/motor evoked potentials (SEP/MEP) – Often used during surgery to monitor pathways so surgeons can remove more tumor safely without causing new deficits. Nature

15. Electrocorticography (ECoG) – Direct recording from the brain surface during surgery can help map seizure foci and guide extent of resection. Nature

E) Imaging tests

16. Brain MRI with and without gadolinium (core test) – Shows where the tumor is and how it infiltrates. IDH-mutant tumors may enhance less vividly than glioblastoma, but grade 3 lesions often show some enhancement and mass effect. ScienceDirect+1

17. Perfusion MRI (rCBV) and diffusion (ADC) – Help judge tumor grade and cellularity. In IDH-mutant astrocytomas, higher rCBV and lower ADC track with higher grade (grade 4 vs grade 3). BioMed Central

18. MR spectroscopy – Looks at tumor chemicals; IDH-mutant tumors can show a 2-hydroxyglutarate peak (a helpful, noninvasive clue to IDH mutation in some centers). PMC

19. Functional MRI and diffusion tractography (DTI) – Map speech, motor, and important fiber tracts to plan safer surgery and reduce postoperative deficits. ScienceDirect

20. Amino-acid PET (e.g., FET-PET or FDOPA-PET) where available – Can better define active tumor versus treatment effect and support biopsy targeting. ScienceDirect

Non-pharmacological treatments (therapies and others)

(Each item explains what it is, its purpose, and how it works.)

1) Maximal safe surgical resection with brain mapping.
Surgery is the first treatment for most patients. The goal is to remove as much tumor as possible without causing a new permanent deficit. “Awake” surgery with direct electrical stimulation to map language or motor areas helps surgeons protect critical brain functions while increasing the fraction of tumor removed. A larger extent of resection is consistently linked with longer survival in diffuse gliomas. PubMed+2New England Journal of Medicine+2

2) Intraoperative MRI (iMRI).
Some centers use MRI during surgery to check for residual tumor while the patient is still in the operating room. If imaging shows tumor left behind, the surgeon can continue safely. Randomized and observational studies show iMRI increases complete resection rates without raising neurological complications. PubMed+1

3) Fluorescence-guided surgery (5-ALA or fluorescein).
Patients drink 5-ALA or receive fluorescein dye so tumor tissue glows under special light, helping the surgeon see invasive margins. Meta-analyses in high-grade glioma show higher complete resection rates with these techniques, which can be used in many anaplastic astrocytomas that enhance. PMC+1

4) Postoperative radiotherapy (RT).
After recovery from surgery, focused external-beam RT treats remaining microscopic disease. For grade 3 IDH-mutant astrocytoma, RT is standard because it prolongs control and survival; typical total doses are ~59–60 Gy in daily fractions. practicalradonc.org

5) Adjuvant temozolomide after RT (timing strategy).
Strictly speaking it’s a medicine, but the strategy belongs here: based on the CATNON trial, adding 12 cycles of adjuvant temozolomide after RT (without mandatory concurrent TMZ) significantly improved overall survival in 1p/19q-non-codeleted anaplastic gliomas—i.e., astrocytoma, IDH-mutant. This established adjuvant TMZ as part of the standard plan. PMC

6) Multidisciplinary tumor board care.
Neurosurgeons, neuro-oncologists, radiation oncologists, neuroradiologists, neuropathologists, rehabilitation and palliative-care clinicians jointly tailor care to tumor genetics, imaging, and your goals. Guideline groups emphasize team-based decision making for diffuse gliomas. PubMed

7) Seizure management and safety education.
About one-third to one-half of patients have seizures. Doctors treat seizures with non-enzyme-inducing anti-seizure medications (such as levetiracetam) and advise on driving, swimming, heights, and work safety. Do not start anti-seizure drugs in people without a history of seizures purely for prevention; SNO/EANO guidance advises against routine prophylaxis. AAN

8) Careful steroid use for brain swelling.
Dexamethasone quickly reduces edema-related headaches or weakness. Use the lowest effective dose, taper as soon as possible, and monitor sugar, mood, sleep, bone health, and infection risk. Steroids relieve symptoms but do not treat the tumor. PMC+1

9) Physical therapy and exercise programs.
Supervised aerobic and resistance exercise improves fitness, fatigue, mood, and quality of life in brain-tumor patients and is considered safe when individualized. Early PT helps maintain mobility and prevent deconditioning. PMC+1

10) Occupational therapy.
OT helps patients adapt to changes in strength, coordination, and vision; teaches energy conservation; and recommends assistive devices so daily activities remain safe and independent. PMC

11) Speech-language therapy and cognitive rehabilitation.
Therapists work on word-finding, comprehension, reading, writing, memory, attention, and executive skills using structured drills and compensatory strategies; this is especially important when tumors are near language networks or after awake mapping. PMC

12) Neuropsychology support and return-to-work planning.
Formal testing identifies cognitive strengths and weaknesses and guides accommodations at work or school (for example, rest breaks, written instructions, or flexible schedules). PMC

13) Tumor Treating Fields (TTFields) counseling.
Wearable low-intensity alternating electric fields slow cell division. TTFields have proven survival benefit in glioblastoma; data in grade 3 IDH-mutant astrocytoma are limited and mainly trial-based, but some centers discuss off-label use case-by-case. Oxford Academic

14) Proton or highly conformal radiotherapy planning.
When tumors are near sensitive structures, proton therapy or highly conformal techniques (IMRT/VMAT) can reduce dose to healthy brain while adequately treating the target. Selection depends on anatomy and access. practicalradonc.org

15) Fertility, family planning, and endocrine care.
Discuss fertility preservation before RT/chemo when pertinent. Long-term steroids or RT can affect hormones; endocrine review helps with bone and metabolic health. PMC

16) VTE (blood clot) prevention and management.
Brain-tumor patients have higher clot risk; clinicians use mobility plans, hydration, and appropriate anticoagulation when indicated, balancing bleeding risk. Oxford Academic

17) Headache, sleep, mood, and fatigue support.
Non-drug strategies (sleep hygiene, relaxation, graded activity, CBT-I, mindfulness) complement medications to improve daily function. PMC

18) Nutritional counseling.
Registered dietitians help maintain weight and muscle, manage steroid-related appetite changes, and ensure safe, balanced diets during therapy. Evidence for special anti-cancer diets in glioma is investigational; any restrictive diet should be in a clinical-trial or supervised program. Oxford Academic+1

19) Palliative-care integration from diagnosis.
Early palliative care focuses on symptom control, coping, and goal-aligned choices; it is not the same as end-of-life care and can be provided alongside active treatment. PubMed

20) Clinical-trial participation.
Trials test promising options like IDH inhibitors for higher-grade disease, vaccines, CAR-T, and oncolytic viruses. Ask about trials at every stage of care. PubMed

---

Drug treatments

(For each: long plain description, class, dose/time, purpose, mechanism, and key side effects.)

1) Temozolomide (TMZ).
Temozolomide is the backbone chemotherapy. It is an oral alkylating agent that adds methyl groups to tumor DNA (especially at O6-guanine) to trigger cell death when the damage is not repaired. In grade 3, IDH-mutant astrocytoma, the CATNON trial showed that adjuvant TMZ after RT improves overall survival; giving TMZ concurrently during RT brought no clear added benefit in that setting. Standard adjuvant dosing is 150–200 mg/m² on days 1–5 every 28 days for up to 12 cycles if tolerated. Main risks are low blood counts, fatigue, nausea, and rare opportunistic infections; blood tests before each cycle are essential. PMC

2) Lomustine (CCNU).
Lomustine is an oral nitrosourea used as an alternative or at recurrence. It crosslinks DNA to block replication in slowly cycling glioma cells. Typical dosing is 110 mg/m² once every 6–8 weeks, adjusted for counts. It can suppress bone marrow, cause nausea, and rarely affect lungs or liver; careful blood monitoring is required. PubMed

3) PCV regimen (Procarbazine, CCNU, Vincristine).
PCV combines three older agents with different actions and schedules (6-week cycles, typically up to 6 cycles). It is sometimes used when temozolomide is not suitable or in specific molecular contexts. Side effects include myelosuppression, neuropathy (vincristine), nausea, and interactions (procarbazine requires strict food/drug cautions). PubMed

4) Bevacizumab.
Bevacizumab is a VEGF-blocking antibody that reduces abnormal tumor blood vessels and brain edema. It can improve MRI changes and symptoms and reduce steroid needs, but has not shown overall-survival benefit in anaplastic astrocytoma; it is used symptomatically or for radiation necrosis. Dose is often 10 mg/kg IV every 2 weeks. Risks include high blood pressure, clots/bleeding, wound-healing problems, and protein in urine. PMC

5) Dexamethasone.
Dexamethasone is a corticosteroid for fast relief of swelling-related symptoms such as headache or weakness. Doses vary widely (for example, 2–16 mg/day) and should be tapered as soon as possible. Side effects can include high blood sugar, mood changes, insomnia, infection risk, muscle loss, and bone thinning; use the lowest effective dose and add bone protection if long-term. PMC+1

6) Levetiracetam.
Levetiracetam is a non-enzyme-inducing antiseizure medicine favored in brain-tumor patients because it lacks major drug-drug interactions with chemotherapy or steroids. Typical dosing is 500–1000 mg twice daily, titrated to effect. It prevents seizures by modulating synaptic vesicle protein SV2A. Possible side effects are sleepiness and mood irritability; vitamin B6 may help in some cases. Do not start prophylactically in patients with no seizures. AAN

7) Valproic acid.
Valproate is an antiseizure drug and histone-deacetylase inhibitor with potential radiosensitizing effects. Some analyses suggest improved survival when given with RT/TMZ, but this remains debated and must be balanced against higher risk of low blood counts. Doses are titrated to therapeutic serum levels. Watch for platelet drop, liver issues, tremor, and drug interactions. PMC+1

8) Enzyme-inducing antiseizure drugs (avoid when possible).
Phenytoin, carbamazepine, phenobarbital, and primidone induce liver enzymes and can lower levels or effectiveness of many anti-cancer drugs. If patients are already on these agents, clinicians consider switching to non-inducing options when safe. PMC+1

9) Mannitol or hypertonic saline (peri-operative).
These IV osmotic agents lower intracranial pressure quickly in emergencies or around surgery by drawing fluid out of swollen brain tissue. They are short-term measures with careful monitoring of electrolytes and kidney function. cns.org

10) Antiemetics (ondansetron, etc.).
To control nausea from chemotherapy, 5-HT3 antagonists like ondansetron are used before TMZ; add dexamethasone-sparing strategies and bowel regimens for constipation. PubMed

11) PJP prophylaxis when indicated.
When patients receive prolonged steroids or lymphocyte-suppressing chemo, doctors may prescribe trimethoprim-sulfamethoxazole (or alternatives) to prevent Pneumocystis pneumonia. The decision depends on counts, steroid dose, and regimen. PubMed

12) Gastric protection when on steroids.
Proton-pump inhibitors or H2 blockers protect the stomach if steroids and anti-inflammatories are needed; use the minimum effective course. cns.org

13) Anticoagulants for blood clots.
Low-molecular-weight heparin or DOACs treat DVT/PE when they occur; choice balances clot control and bleeding risk in brain-tumor patients. Oxford Academic

14) Pain medicines in a stepwise plan.
Acetaminophen and carefully chosen opioids manage pain flares; avoid NSAIDs near surgery or with thrombocytopenia; neuropathic agents help nerve-type pain. PubMed

15) Mood and sleep medicines when needed.
Short-term agents (e.g., melatonin for sleep, SSRIs for depression/anxiety) can improve coping; interactions with antiseizure drugs are checked first. PubMed

16) IDH-pathway inhibitors (research/selected use).
The oral IDH1/2 inhibitor vorasidenib is approved for grade 2 IDH-mutant glioma after surgery; other IDH inhibitors (e.g., ivosidenib) have early-phase data in gliomas. For grade 3, use is investigational or highly individualized; ask about trials. PubMed

17) TTFields device supplies and skin care.
Using TTFields requires scalp arrays and skin care medicines (steroids/antibiotics creams) to prevent irritation. Benefit outside GBM is unproven; decisions are individualized. Oxford Academic

18) Agents for radiation necrosis.
In symptomatic radiation necrosis, bevacizumab can reduce edema and improve symptoms; steroid-sparing is a common goal. Dosing often 7.5–10 mg/kg every 2 weeks for several doses. PMC

19) Second-line alkylators (temozolomide rechallenge or dacarbazine).
At recurrence after a long TMZ-free interval, a “rechallenge” or switch to another alkylator can be considered; benefit varies. PubMed

20) Clinical-trial immunotherapies (vaccines, CAR-T, oncolytic viruses).
These drugs try to help the immune system recognize tumor cells. The DCVax-L vaccine showed a survival signal in GBM using external controls; CAR-T and oncolytic viruses (e.g., DNX-2401) are promising but still experimental with variable efficacy. Access is typically through trials and not routine care for grade 3 astrocytoma. JAMA Network+1

---

Dietary molecular supplements

Important note: No supplement has been proven to treat or cure grade 3 astrocytoma. Use supplements only with your oncology team, mainly to correct true deficiencies or for general health; some products interact with chemo or raise bleeding risk.

1) Vitamin D (correct deficiency).
Many adults are low in vitamin D. Repleting deficiency supports bone health during steroids and inactivity; some observational data link vitamin D use with better outcomes in brain-tumor patients, but this is not proof of anti-tumor effect. Dosing: individualized to blood level (e.g., 1000–2000 IU/day or short loading courses per labs). Mechanism: hormone-like effects on cell growth and immunity. Oxford Academic+1

2) Calcium (with vitamin D) for bone protection.
Steroids weaken bone; standard-dose calcium plus vitamin D helps prevent bone loss, sometimes with bisphosphonates if risk is high. Oxford Academic

3) Omega-3 fatty acids.
Omega-3s support cardiovascular health and may reduce inflammation. There is no proven anti-glioma effect. Typical supplemental doses are 1–2 g/day EPA+DHA if diet is low and bleeding risk is acceptable. PubMed

4) Fiber and whole-food nutrition.
A balanced diet rich in plants supports bowel health during opioids and antiemetics and helps energy levels. No specific “anti-glioma” diet is validated; extreme diets can cause weight loss. Oxford Academic

5) Ketogenic diet (investigational).
Early clinical studies and ongoing trials explore very-low-carb diets to stress tumor metabolism. Some small studies suggest feasibility and possible benefits, but evidence is not definitive; strict ketogenic diets should only be done under a clinical trial or expert dietitian because of risks (weight loss, lipid changes). Clinical Trials at UCSF+1

6) Probiotics (symptom-focused).
Probiotics may help some people with constipation or antibiotic-associated diarrhea during treatment, but quality varies and immune-suppressed patients need caution. PubMed

7) Magnesium (if low).
Correcting low magnesium can reduce cramps and help sleep; high doses can cause diarrhea and interact with some meds. PubMed

8) Multivitamin at standard dose.
A simple daily multivitamin can fill small gaps but has no proven tumor effect. Avoid mega-dose antioxidants during RT/chemo unless your oncologist agrees. SAGE Journals

9) Melatonin (sleep).
Melatonin can improve sleep quality; data for anti-cancer effects are limited and inconsistent. Typical doses 1–5 mg nightly. PubMed

10) Protein supplements when appetite is poor.
Whey or plant protein shakes maintain lean mass if regular meals are hard; choose low-sugar options and coordinate with dietitians. PubMed

---

Immunity booster / regenerative / stem-cell” drugs

There are no approved regenerative or stem-cell drugs that cure astrocytoma. Below are research-stage approaches you may hear about—available mainly in clinical trials.

1) Dendritic-cell vaccines (e.g., DCVax-L).
These vaccines load the patient’s own immune cells with tumor antigens to educate T cells. In GBM, DCVax-L showed longer survival than external controls; access is limited and results do not yet change standard treatment for grade 3 astrocytoma. JAMA Network

2) CAR-T cell therapies (e.g., EGFRvIII, IL13Rα2 targets).
CAR-T cells are engineered to recognize tumor antigens and attack. Early GBM trials show safety but modest responses so far; research continues to improve persistence and target selection. MDPI+1

3) Oncolytic viruses (e.g., DNX-2401).
These modified viruses infect and kill tumor cells and may spark immune responses. Trials in recurrent high-grade gliomas show occasional deep, durable responses, but median outcomes remain limited; combinations with immunotherapy are under study. Nature

4) IDH inhibitors (e.g., vorasidenib/ivosidenib).
These block the abnormal IDH enzyme and lower the oncometabolite 2-HG. Vorasidenib is approved for grade 2 disease; for grade 3, use is investigational or individualized. PubMed

5) Personalized neoantigen vaccines.
Computers identify mutations unique to a tumor, and a vaccine is made to target them. This is experimental and available only in trials. PubMed

6) Checkpoint inhibitors (PD-1/PD-L1)
These immune drugs have not shown consistent benefit in unselected diffuse gliomas; trials continue in biomarker-selected groups or in combinations. PubMed

---

Surgeries

1) Awake craniotomy with language/motor mapping.
Used when tumors are near eloquent cortex to maximize tumor removal while preserving speech or movement. Mapping lowers long-term neurological and language deficits and improves chances of a more complete resection. PubMed

2) Standard craniotomy under general anesthesia with subcortical mapping.
For tumors not suitable for awake techniques, surgeons still use electrical mapping/monitoring to protect pathways while removing tumor aggressively. ScienceDirect

3) Intraoperative MRI–guided resection.
Performed to detect and remove residual tumor during the same operation, increasing gross total resection rates. PubMed

4) Fluorescence-guided resection (5-ALA or fluorescein).
Dye makes tumor glow to help visualize margins and increase safe resection, especially in enhancing, high-grade areas. PMC

5) Stereotactic biopsy (needle biopsy).
If the tumor is in a deep/critical location or the patient is not a surgical candidate, a small tissue sample is taken to determine the exact type and molecular markers, guiding RT/chemo plans. PubMed

---

Prevention points

There is no proven way to prevent astrocytoma. The best “prevention” is fast evaluation of new neurological symptoms and controlling known risks where possible.

1. Avoid unnecessary ionizing radiation to the head. Medical imaging uses the lowest dose needed. ResearchGate

2. If you have a strong family history or a known syndrome (e.g., Li-Fraumeni, NF1), seek genetic counseling and surveillance plans. NCBI

3. Use helmets and safety gear to reduce head injuries (not a proven glioma cause, but good brain health). PubMed

4. Do not smoke; keep blood pressure, lipids, and glucose controlled to protect the brain generally. PubMed

5. Maintain healthy sleep, activity, and diet to support resilience during treatment. PMC

6. Keep vaccinations up-to-date; discuss timing if on chemo or steroids. PubMed

7. Review workplace chemical exposure policies; some solvents and vinyl chloride are under study—avoid unnecessary exposure. Cancer.gov

8. Seek early care for persistent headaches, seizures, or new neurological deficits. AANS

9. Plan bone protection if long steroid courses are expected (vitamin D, calcium, weight-bearing exercise). Oxford Academic

10. Keep follow-up MRIs on schedule; early detection of recurrence allows more options. practicalradonc.org

---

When to see a doctor urgently

Go to emergency care for a first-time seizure, sudden weakness on one side, sudden trouble speaking or understanding, sudden severe headache, repeated vomiting, sudden vision loss, or rapidly worsening confusion. These can signal swelling, bleeding, or seizures and need urgent treatment and imaging. AANS

---

What to eat and what to avoid

What to eat.
Choose a balanced, Mediterranean-style pattern: fruits, vegetables, legumes, nuts, whole grains, lean proteins (fish, poultry, eggs, tofu), fermented dairy or yogurt if tolerated, olive oil, and plenty of water. Aim for enough calories and protein to prevent weight loss, especially during RT/TMZ. If appetite is low, consider small frequent meals and protein smoothies. Work with an oncology dietitian for individualized plans. Oxford Academic

What to avoid.
Avoid crash diets and extreme supplement megadoses during active treatment unless part of a study. Be cautious with herbal products that can thin blood or interact with antiseizure drugs. Do not start a ketogenic diet on your own; consider only within a clinical trial or under expert supervision. Limit alcohol and avoid smoking. SAGE Journals+1

---

Frequently asked questions

1) Is “anaplastic astrocytoma” the same as grade 3 IDH-mutant astrocytoma?
Mostly yes. The 2021/2024 WHO system uses “astrocytoma, IDH-mutant, CNS WHO grade 3,” replacing the older term in most cases. PMC

2) What is the usual first treatment?
Maximal safe surgical resection, followed by radiotherapy and then adjuvant temozolomide for up to 12 cycles based on CATNON. PMC

3) Does MGMT methylation matter in grade 3 IDH-mutant tumors?
Unlike glioblastoma, MGMT methylation is not clearly predictive for TMZ benefit in IDH-mutant anaplastic astrocytoma; adjuvant TMZ is recommended regardless. PMC+1

4) Do I need anti-seizure medicine if I never had a seizure?
No. Guidelines advise against routine seizure-drug prophylaxis in seizure-free patients with brain tumors. AAN

5) Will steroids treat the tumor?
No. Dexamethasone reduces swelling and symptoms but does not kill tumor cells; use the lowest dose for the shortest time. PMC

6) How important is the extent of resection?
Very important—greater removal is linked to better survival, but safety and function come first; mapping and iMRI help. ScienceDirect

7) Are TTFields part of standard care?
TTFields are standard in glioblastoma, not established in grade 3 astrocytoma; consider trials or individualized decisions. Oxford Academic

8) Are IDH inhibitors standard for grade 3?
Not yet. They’re approved for certain grade 2 IDH-mutant gliomas; for grade 3, use is investigational. PubMed

9) Can immunotherapy cure this cancer?
Current immunotherapies (vaccines, CAR-T, oncolytic viruses) show promise in trials but are not curative or routine for grade 3. JAMA Network+1

10) What is the role of ketogenic diets?
Research is ongoing; do not self-start. Potential benefits are unproven, and risks exist—consider only with trial/dietitian oversight. Clinical Trials at UCSF

11) Should I avoid certain seizure medicines?
Yes—avoid enzyme-inducing antiseizure drugs (like phenytoin, carbamazepine) if possible because of interactions with cancer treatments. PMC

12) What imaging will I need after treatment?
Regular MRI scans (e.g., every 2–4 months initially) to monitor for response or recurrence; advanced sequences help distinguish treatment effect from progression. Frontiers

13) Is radiation re-treatment possible if the tumor comes back?
Sometimes. Careful re-irradiation can be considered in selected patients after multidisciplinary review. thegreenjournal.com

14) Can exercise help?
Yes. Individualized exercise improves fitness, fatigue, and quality of life and is safe in brain-tumor patients when properly supervised. PMC

15) Where can I read clinician-level guidance?
See EANO diffuse glioma guidelines and the NCI PDQ for clinician summaries; they are updated and open-access. PubMed+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.